• ABPI Website
  • Ukraine - UK Pharmaceutical Industry Response
Ukraine - UK Pharmaceutical Industry Response We stand in solidarity with the people of Ukraine and condemn the invasion of their country. As an industry dedicated to saving lives, we stand for peace.

The Association of the British Pharmaceutical Industry is leading the UK Industry’s role in the global response to the Ukraine crisis and supporting the mission of the broader sector and of the European Federation of Pharmaceutical Industries and Associations.

ABPI and EFPIA Logos

The research-based pharmaceutical industry in Europe stands in solidarity with the people of Ukraine. We condemn the invasion of their country and express our sorrow at the suffering it has caused. As an industry dedicated to saving and improving lives, we stand for peace.

Our first priority is to ensure that medicines reach the patients that need them in Ukraine, in the neighbouring EU Member States, in Russia and in other countries where access to medicines may be negatively impacted. We call on all parties to facilitate the safe passage of medicines and vaccines to those in need.

Our Member Companies and Associations are offering humanitarian support both in Ukraine and for the emerging refugee crisis in neighbouring EU Member States. This includes in kind donations of medical supplies and financial support to NGOs.

As a health-based industry and part of the wider EU healthcare community, we will work together to address the health needs of all those affected by this war, in Ukraine and in neighbouring countries as part of the wider humanitarian relief effort.

Humanitarian response

Our member companies are offering humanitarian support both in Ukraine and for the emerging refugee crisis in neighbouring countries. This includes in kind donations of medical supplies and financial support to NGOs. Read the EFPIA Statement on the crisis in Ukraine.


AbbVie's response to the Ukraine crisis

AbbVie's thoughts are with the people of Ukraine and those affected across the region. As a global biopharmaceutical company, they have a responsibility to patients who depend on their medicines. They are committed to ensuring their patients in Ukraine, Russia and throughout the region continue to have access to their essential and life-saving medicines.

AbbVie's presence in Ukraine and throughout the region

Their priority is to ensure the safety of their colleagues and help patients get the medicines they need.

As the tragic events continue to unfold in Ukraine, AbbVie has temporarily suspended operations for all their aesthetics products in Russia.

They do not have any manufacturing plants in the region. Importantly, AbbVie continue to monitor the safety of their employees in Ukraine and the surrounding region.

Status of Clinical Trials

AbbVie is doing everything possible to minimize disruption to the treatment and care of their patients and clinical trial participants. They have paused the start of new clinical studies and the screening and enrolment of clinical trial participants in ongoing studies in Ukraine and Russia. AbbVie are committed to ensuring their clinical trial participants have access to the investigational medicines they need.

Humanitarian / Philanthropic response

AbbVie's philanthropic focus is on humanitarian, employee, and donation support.

AbbVie is:

  • Donating a total of USD 1 million to non-profit partners for medical care and supplies for Ukraine and Ukrainian refugees.
  • Donating essential medicines to the Ukrainian government and their disaster relief partners.
  • Providing relief and additional financial support as needed to Ukrainian employees and their immediate families.
  • Doubling the AbbVie Foundation's employee donation match for select disaster relief partners with active humanitarian relief efforts in Ukraine and surrounding countries.

As this situation evolves, AbbVie will continue working with their non-profit partners and employees to support relief efforts as they hope for a peaceful resolution.


Almirall stands in solidarity with everyone who is suffering first-hand the consequences of the conflict and humanitarian crisis in Ukraine.

As a company Almirall are also committed to helping the humanitarian relief efforts and they have launched the giving campaign “Together with Ukraine” that is matching employee donations globally. All funds raised will be donated to the Spanish Red Cross (Cruz Roja Española), who will support the Ukrainian Red Cross response as well as regional Red Cross efforts in neighbouring countries.

Almirall is also accelerating donations of relevant medicines to NGOs operating in Ukraine and bordering countries. In the next few days, they will send a total of more than 150,000 units of relevant medicines.

As a global biopharmaceutical company, Almirall uphold respect for fundamental human rights around the world as part of their purpose to improve people’s lives.


The Amgen Foundation has approved a disaster relief grant of USD 500,000 in total, which will be split between International Medical Corps and Project Hope.

They have also opened the Amgen Foundation Disaster Relief Matching Gifts Program, allowing all staff globally to receive the Foundation match when they donate to select charities to support humanitarian efforts related to the conflict in Ukraine.


Thoughts at Astellas are with the people of Ukraine, and they hope for a swift and peaceful resolution to the situation.

Their priority is on the safety of Astellas Ukraine employees and their families. Also, they are ensuring on-going partnership and connectivity with suppliers, distributors and key stakeholders to do their best efforts for continuous supply for patients.

Astellas have taken steps to support the people in Ukraine. They are donating 10 million yen to UNICEF to support their humanitarian effort. They are also looking at other philanthropic options including essential drug donation and fund raising.  

At Astellas, they are at the forefront of healthcare change to turn innovative science into VALUE for patients. They remain committed to our mission in all the countries where we operate.  


AstraZeneca continue to provide urgent humanitarian support in Ukraine and neighbouring countries. To date, they have committed over USD 7 million to response efforts, including donations of:

  • Twenty-four pallets of medicines, worth USD 3 million, to their humanitarian relief partner Direct Relief, which is working directly with the Ukrainian Ministry of Health.
  • USD 2 million to support relief agencies working in Ukraine, Poland and surrounding areas with a focus on providing healthcare and humanitarian assistance to those affected by the conflict. Funding is being provided to Project HOPE, working with and through the World Health Organization, and International Medical Corps.
  • Medicines via The Red Cross affiliates in neighbouring countries to respond to the unfolding refugee crisis.
  • >USD 1 million  to UNICEF and The Red Cross, including over USD 500,000 of employee donations, which AstraZeneca is matching.


Bayer stand by the people of Ukraine who can fully count on their solidarity and support, and will do everything in their power to live up to their responsibility to reduce the suffering caused by this terrible war.

Bayer announced a EUR 3 million disaster relief fund to strengthen emergency measures in response to the invasion of Ukraine. The support fund is benefiting international and local humanitarian aid organisations engaging in Ukraine and Eastern European neighbouring states. The fund includes the company’s initial humanitarian response released only one day after the first attacks, making EUR 300,000 available for immediate aid by the German Red Cross and local organisations. In particular, we delivered financial support to the “Kharkiv with You” Charitable Foundation in the amount of EUR 50 thousand for the essential hygiene products and food for residents of Kharkiv and nearby towns.

Additional product donations for the population of Ukraine amount to EUR 2.4 million in numerous cases. In particular, at the request of the Ukrainian Ministry of Health and the National Cancer Institute, Bayer donated antibiotics to help up to 30,000 Ukrainian patients, as well as medicines in the areas of anti-inflammatory, cardiovascular, antihistamine, cancer, diagnostic, and skin diseases treatment.

Bayer's employees worldwide also responded generously – donating more than EUR 1 million through the Red Cross relief campaign. Additionally, Bayer colleagues have set up a platform where employees offer housing and support to colleagues from Ukraine and their families who may need temporary shelter.

Also, as the company working in the field of agriculture, Bayer strives to support protecting food supply chains from further disruption. Our seeds and agricultural inputs stand ready for the planting season for farmers in Ukraine. In addition to this, Bayer has donated more than 40,000 bags of seeds to grow food on nearly 30,000 hectares to support 1,250 small Ukrainian farmers


Biogen are heartbroken by the war in Ukraine and stand firmly with the global community in providing humanitarian aid.

Consistent with their values, the Biogen Foundation has launched a giving campaign that is doubling employee donations.

Together, with their employees across the European region and around the world, they have already raised more than USD 350,000 and counting, to provide medical supplies, food, water, shelter and other essential support.

They are closely monitoring this evolving situation and will continue to explore additional ways to help their neighbours in need.

Boehringer Ingelheim

Boehringer Ingelheim condemns the military aggression against Ukraine.

“On behalf of the Board of Managing Directors, I would like to express our feelings of sorrow and consternation over the start of a war in the middle of Europe. This affects people across the region, where families have members on both sides of the border, and where sons and daughters are called to duty in a war that only brings suffering and pain”, says Hubertus von Baumbach, Chairman of the Board of Managing Directors. “War can never be accepted as the means of resolving conflicts.”
It was in February 1992 that we established our presence in Ukraine and Russia, which has grown to a total of nearly 800 employees today. "During these 30 years, we have achieved many milestones together in the interest of health, for the benefit of patients, and in the interest of life. Our Ukrainian as well as Russian colleagues have become integral members of the Boehringer Ingelheim family,” Hubertus von Baumbach continued. "Our thoughts are with them, as well as the many people who simply want to live in peace. On behalf of my colleagues, my deepest sympathies are with them all.”
“We have decided to make a donation of EUR 2.5 million* to charitable organisations providing humanitarian support to Ukraine and its citizens.”

Many Boehringer Ingelheim colleagues are working to ensure the safety and well-being of their employees and their families in any way possible. They are in close contact with their Ukrainian colleagues. At the same time, they are seeking to limit the impact of the conflict on the supply of medicines to patients for humanitarian reasons across both countries. “We would like to thank all who have worked tirelessly during the past days to provide help wherever help can be provided.” Hubertus von Baumbach promises: “We will do everything to help our impacted colleagues, their families and communities.”

Boehringer Ingelheim realise that the war will have a long-term impact. They will therefore donate 12 monthly payments of each EUR 1 million to the Polish and German Red Cross organisations, from this month (March).

* The donation will be distributed to the following charitable organisations:

Read more on the Boehringer Ingelheim website.

Bristol Myers Squibb

Bristol Myers Squibb and the Bristol Myers Squibb Foundation are each actively contributing to relief efforts in Ukraine, donating more than USD 1 million total to date.

The Company has provided donations to a number of organisations coordinating relief efforts; this includes activities organized by the World Institute on Disability and the ECO-ASCO special network, working with WHO Europe to pool information to aid the coordination of transfer and care for Ukrainian cancer patients.

The Bristol Myers Squibb Foundation has provided donations to organisations, including Americares, Direct Relief, International Rescue Committee, and Save the Children.

The Foundation is also matching contributions by their employees globally to organisations providing relief to Ukraine.


Chiesi announced an initial donation of EUR 1 million, part of which has already been committed to support humanitarian NGOs such as the Croce Rossa Italiana and UNHCR Italia, Agenzia ONU per i Rifugiati, operating in Ukraine and a fund for the reception of refugees on the Italian territory and they are currently working to identify further solidarity initiatives for the war-affected populations. Chiesi will continue to prioritise uninterrupted access to their treatments to patients in Ukraine and Russia, despite the unstable situation.

Daiichi Sankyo

To support humanitarian aid for those impacted by the conflict, Daiichi Sankyo Company, Limited will donate USD 1 million (approximately 115 million yen) to the United Nations Children's Fund (UNICEF). 

Multiple Daiichi Sankyo group companies are likewise donating, by contributing to their local charities and leveraging gift matching programs, adding to their overall support for those affected by this conflict. Daiichi Sankyo are also thankful to their many employees who are helping privately, including by hosting refugees in their homes.

Daiichi Sankyo are working with their partners across the globe to ensure, as much as possible, that patients retain access to their medicines and their clinical trials worldwide.


Eisai share deep concern about the situation in Ukraine and sincerely hope that safety and peace will return to that country as soon as possible.

Under its hhc philosophy to increase the benefits that medicines bring to patients and their families, the Eisai Group, as an international pharmaceutical company, strives to contribute to the health and well-being of all people, wherever they may be.

To further this mission, Eisai are working with various partners including the International League Against Epilepsy to make their medicines available to those patients who have been displaced by the war in Ukraine and who are in desperate need of medication. In addition, as humanitarian support to those who have been severely affected in Ukraine and those who have been evacuated to the surrounding countries, the Eisai Group has donated approximately 16 million yen to the Japanese Red Cross Society, the international non-governmental organization Association for Aid and Relief (AAR), Japan and other organisations.


Gilead is working closely with their distribution partners, humanitarian and non-governmental organisations, to help get their medicines to those who need them. They are also liaising closely with the local health ministries in countries bordering the conflict zone to offer assistance to Ukrainian refugees who may need quick access to their medicines.

Gilead has also donated USD 3 million to support the humanitarian response. The funds are going to UN Refugee Agency to deliver emergency aid to civilians; UNICEF USA to meet urgent and escalating needs for safe water, health care, nutrition and protection; and International Medical Corps to distribute donations, food and medical supplies to those who have been displaced.


Grünenthal has donated EUR 400,000 to the Red Cross to support humanitarian relief efforts in Ukraine and Eastern Europe. In addition, Grünenthal partners with Action Medeor and the University Hospital RWTH Aachen to provide urgently needed pain medication to the region. The first transport with medicine is set to leave their headquarters 7-11 March 2022. 


Alongside the global community, GSK share deep concern about the tragic events happening in Ukraine. They are taking actions guided by their purpose, and as a company dedicated to health and care for people and patients.

Our first priority is the safety, security and wellbeing of GSK people, wherever they are located. After this, our focus is to make sure their products reach the people who need them, including supporting humanitarian efforts in Ukraine and surrounding countries.

GSK condemn the fighting and the harm and suffering it’s causing to people in Ukraine and beyond. The actions taking place are in violent contradiction to their purpose, and unshakeable belief that all people should be treated with dignity, respect and humanity.

For full information on GSK’s humanitarian support and GSK in Russia, please visit GSK.com [Our response to the situation in Ukraine | GSK].


Ipsen is providing humanitarian relief to the people of Ukraine via a donation of EUR 1.5 million, split between two humanitarian organisations.

  • Tulipe collects donations from health companies to respond to the emergency needs of populations in distress during acute health crises, natural disasters and conflicts via its partners in the field.
  • The Red Cross in France an independent charity working alongside governments and public authorities which undertakes neutral and impartial humanitarian action.

Johnson & Johnson

Johnson & Johnson is:

  • Donating USD 5 million to support the work of the International Rescue Committee (IRC) and International Federation Red Cross and Red Crescent to provide humanitarian support for refugees in the border countries.

  • Providing product donations including hygiene kits, health packets and medical supplies.

  • Launching an unlimited matching program for Johnson & Johnson global employees with Global Giving Ukraine Crisis Relief Fund.

  • Continuing to work with their longstanding partners in global health—International Health Partners (IHP, UK), Americares (US), Direct Relief (US), IFRC, Save the Children and UNICEF—to support those in the region by providing them access to the Johnson & Johnson supply chain network to strengthen their reach and capabilities.

LEO Pharma

LEO Pharma stands united with the people of Ukraine and with the international community in condemning the invasion.

As of March 22nd 2022, LEO Pharma has decided to donate close to 740,000 packs and 420,000 vials of antibiotics and anticoagulants via International Health Partners. These medicines are relevant for treating wounds, infections and saving lives to support people in vulnerable communities in Ukraine.

The products have an estimated value of EUR +1.8 million and is a donation on top of the DKK 1 million (EUR 135,000) donated to the Danish Red Cross.


Lilly is donating USD 7.5 million of insulin to Project Hope, a U.S. non-profit organization that empowers health care workers facing the world’s greatest health crises to build resilient communities and a healthier, more equitable world. Project Hope is currently on the ground in Ukraine and is actively shipping essential medicines and medical supplies to assist Ukrainians.

Support for Relief Organisations 

The Lilly Foundation is also making two equal monetary contributions totalling USD 500,000 to Direct Relief and to Americares to support their respective relief efforts in the region. Americares is currently working to deliver aid for families facing crisis in Ukraine. They are collaborating closely with the World Health Organization, regional health authorities, and international, national and local response organisations in Ukraine and neighbouring countries.

The Lilly Foundation will also match eligible Lilly employee donations up to an additional USD 500,000. They hope for an immediate end to the hostilities and a peaceful resolution to this crisis as soon as possible. 

More information is available here Lilly Ukraine Support | Eli Lilly and Company

*The Eli Lilly and Company Foundation, Inc. is a separate, tax-exempt organization.


Lundbeck donated DKK 10 million (approximately USD 1.5 million) to the Danish Red Cross to support the emergency relief efforts and are exploring ways to donate essential medicines to the people who rely on them.

Their priority has been and will continue to be to take care of their colleagues and patients both in Ukraine and Russia that are innocent people in the midst of war.


  • To support humanitarian aid in Ukraine, Merck has donated EUR 2 million to the German Red Cross. EUR 1 million of this amount were contributed by the Merck Family.
  • In addition, Merck have created a donation platform to enable employees at Merck to also contribute. Donations made here will be matched by the company. Our employees have already donated close to EUR 550,000 (Status: March 30)
  • Merck colleagues across the company, particularly in countries bordering on Ukraine such as Poland, are volunteering to support in any way they can: Welcoming Ukrainian refugees to their homes, organising the transportation of care packages with food and hygiene products and connecting on their intranet as well as locally to share information about ways to help and donate.
  • Merck employees in Darmstadt and Gernsheim in Germany donated seven metric tons of urgently needed relief supplies such as non-perishable food, hygiene items, sleeping bags, bedding and blankets, strollers and toys. In addition, Merck donated eight metric tons of non-perishable food and first-aid kits. All relief items went to the Polish NGO “Centrum Sektor 3”, which is providing humanitarian aid to Ukrainian refugees who have arrived in Wroclaw since the beginning of the war.
  • In response to an open request from the Ukrainian government, Merck have supplied 23,000 litres of disinfectants manufactured by Merck for use by their civilian population. Distribution is being managed by the Hessian government.


MSD has a more than 130-year legacy of saving and improving lives around the world, and they remain committed to doing so. MSD are saddened by the invasion of Ukraine and stand united with the Ukrainian people who face a humanitarian crisis. MSD’s hope is for an urgent resolution, and their paramount concerns are the safety and well-being of their employees and ensuring their patients and customers have continued access to Merck medicines and vaccines.

For humanitarian reasons, MSD has a responsibility to continue to supply lifesaving medicines and vaccines to patients and animals in Russia. In light of the invasion of Ukraine, however, the company will not make further investments in Russia. MSD currently does not have research or production facilities in Russia and is operating in compliance with all international sanctions while working to ensure access to critical treatments.  

During this time of tragedy, MSD’s commitment to helping the people affected is unwavering. Merck are using their resources to help alleviate the human suffering in Ukraine. MSD is taking various actions to address the humanitarian crisis, which include the: 

  • Delivery of molnupiravir to Ukraine through a supply and purchase agreement they have with the government.
  • Donation of molnupiravir to Direct Relief for distribution to refugees. Merck are preparing to donate additional courses specifically for people affected by the invasion of Ukraine.
  • Donation of product, including PROVENTIL, an inhaler used in patients with asthma and TIENAM IV (marketed as PRIMAXIN in the U.S.), an antibiotic used to treat infections in hospitalized patients and KEYTRUDA for existing patients in need. Merck are actively assessing needs for additional products.
  • Commitment of USD 1 million to NGOs, including USD 300,000 to the American Red Cross, delivering urgent assistance to those affected in the region.
  • Utilisation of their donation program for U.S. and Puerto Rico employees to donate to Ukraine relief efforts. Contributions will be matched 100% by the Company. Employees outside of the U.S. can receive a company match toward their donation to the Red Cross and to Direct Relief, and the contribution will be matched 100% by the company.
  • Donation of vaccines from MSD Animal Health to farmers in Ukraine to support the continued raising of livestock and food production. 

As of April 13, their total cash and product donations amount to more than USD 95 million.

MSD will continue to monitor this tragedy and update its response as this crisis unfolds. The focus now remains on supporting the well-being of their employees and doing what they can to ensure access to their medicines and vaccines, and further using our resources to alleviate the unimaginable human suffering in Ukraine.


Novartis condemns the war in Ukraine. This unprovoked act of violence harms innocent people and defies their mission to improve human health globally.

As a medicines company, in the last few days, Novartis have delivered more than 600 thousand packs of antibiotics, painkillers, cardio-vascular, and oncology treatments to maintain supply to those who rely on these drugs in Ukraine and in the border areas where people are seeking refuge.

Novartis has also made an initial USD 3 million donation to charities supporting refugees and displaced people in Ukraine and bordering countries. Novartis are continuing to support their employees and their families in Ukraine, and those who have left the country. Their thoughts are with the citizens of Ukraine, Novartis will continue to contribute to the humanitarian efforts in and for the people of the country.

Novartis remain committed to providing access to medicines to patients in every country where they operate. At the same time, Novartis are careful to comply with the international sanctions imposed upon Russia. 

Novartis have implemented a package of measures that include suspending capital investments, media advertising, and other promotional activities in Russia. In addition to that, while they remain committed to provide access to our medicine in Russia, Novartis responsibly pause the initiation of new clinical trials and the enrolment of new study participants in existing trials. These measures will be kept under review.

Novartis are hopeful that the war in Ukraine will soon reach a peaceful resolution.

Novo Nordisk

The Novo Nordisk Foundation has donated DKK 55 million (approx EUR 7.4 million) to the efforts, including DKK 5 million  (approx EUR 700,000) to the UNHCR – the UN’s refugee agency - to provide urgent support and protection to people forced to flee their homes.

With normal supply chains disrupted, they are in dialogue with several international humanitarian organisations to provide relief and have donated medicines and supplies to the Ukrainian Ministry of Health.

They are doing all they can to maintain the supply of essential medicines to patients living with chronic diseases in Ukraine.


As the humanitarian crisis deepens in Ukraine, all at Otsuka watch with great sadness and a feeling of helplessness. The impact on the people in Ukraine and those fleeing their homes is unimaginable and we hope that their donation of EUR 100,000 to the British Red Cross will contribute to providing a degree of safety and security to those affected by this humanitarian crisis. Otsuka continue to monitor the situation and respond with support where they can.


Pfizer stands with the unified global community across the public, private and civil society sectors in opposition to the Russian war in Ukraine and the brutal situation it has created. Deeply concerned by the human suffering we all are witnessing during the ongoing crisis in Ukraine, Pfizer is committed to contributing to ongoing humanitarian efforts that support the safety, health and wellbeing of people affected by these tragic events.

Through The Pfizer Foundation*, they have provided USD 2 million in humanitarian grant funding to the following organisations working in Ukraine and surrounding countries:

  • American Red Cross to support emergency teams in Ukraine and surrounding countries who are working to repair vital infrastructure, support health facilities with medicines and equipment, and support families with food and hygiene resources. Funds donated through the American Red Cross will support the Ukrainian Red Cross response, as well as regional Red Cross efforts in surrounding countries to support immediate needs of affected populations.
  • International Medical Corps (IMC) to support essential emergency and primary health services, mental health and psychosocial support services, and protection and gender-based violence services, which are critical for conflict-affected communities. COVID-19 awareness and prevention services will be incorporated into these efforts to help keep displaced people safe from the pandemic.
  • International Rescue Committee (IRC) to support their efforts in bordering countries to mobilise resources and connect with partners to help provide life-saving support to people forced to flee their homes.
  • The UN Refugee Agency (UNHCR) to support emergency relief priorities in Ukraine and immediate needs of displaced populations in surrounding countries now hosting Ukraine refugees. UNHCR is the leading UN agency coordinating all inter-agency regional efforts across UN agencies, NGOs and other relevant partners to maximize and effectively coordinate refugee response efforts.

Pfizer have launched the Ukraine Humanitarian Disaster Campaign to provide all eligible colleagues the opportunity to donate to key organisations helping those impacted by the conflict in Ukraine and neighbouring countries. The Pfizer Foundation* is matching colleague financial donations made through this campaign to organisations including UNICEF, the International Rescue Committee, Save the Children, the American Red Cross, CARE, Nova Ukraine and Sunflower of Peace. 

  • As of March 11, 2022, thousands of colleagues from nearly 54 countries have donated nearly USD $621,000.
  • Including The Pfizer Foundation’s dollar-for-dollar match, the total donation is approaching USD 1.25 million.

Pfizer have received detailed requests from the Ukrainian Ministry of Health through their NGO partners for medicines and vaccines and have responded with donations both from their existing supply in Ukraine and from the U.S. These donations — which include nearly 700,000 doses of lifesaving antibiotics, antifibrinolytics, and oncology medicines — are intended to help healthcare providers and relief workers treat patients in Ukraine and neighbouring countries.

Bearing in mind the exception of medicines from the international community’s sanctions on Russia, Pfizer has concluded that a voluntary pause in the flow of our medicines to Russia, including cancer and cardiovascular therapies, would cause significant suffering and potential loss of life, particularly among children and older people. Pfizer will donate all profits of our Russian subsidiary to causes that provide direct humanitarian support to the people of Ukraine.

*The Pfizer Foundation is a charitable organization established by Pfizer Inc. It is a separate legal entity from Pfizer Inc. with distinct legal restrictions.


Roche vehemently condemns the violent invasion of Ukraine. They are doing everything necessary to safeguard and support their employees and their families whilst also ensuring global supplies of their products.

Roche are working diligently to support the country and people of Ukraine with medical products in accordance with Roche’s overall mission. As a first initiative, they donated a critical antibiotic and specialised medicines for the treatment of anaemia, a wide variety of bacterial infections, influenza, rheumatoid arthritis, SMA and various cancers as well as rheumatoid arthritis and COVID-19. They also donated reagents and consumables for automatic testing of blood donations and units for diabetes management.

They remain in contact with multiple global and local partners as well as charities to understand how it can best continue to support the people of Ukraine with additional medical supplies.

Ensuring critical medicines and diagnostics reach the people who need them is extremely important to them and they are making every effort to ensure continued supply within the scope of the available possibilities.

Roche are working with local distributors in Ukraine, and have set up a remote support system for laboratories, through their Diagnostics Customer Support Center in Poland.

They have established a global hotline number and invite patients, caregivers, physicians, clinical trial participants, investigators or coordinators, and healthcare providers to call. The Roche team will do its best to provide everyone who is in need with the appropriate information and support. The hotline is available in multilingual and can be reached on the following number:  +36 146 182 58.

The situation is evolving quickly and further details will be shared when available.

Find more information about their donations here:


Sanofi are deeply saddened by the magnitude of the challenges facing the Ukrainian people.

The safety of their employees is their priority, and all of their teams are working tirelessly every day to support them and their families in every possible way.

Since the beginning of the war, Sanofi have worked to provide patients in Ukraine access to their vital treatments and to mitigate the impact of the situation on their ongoing clinical trials in the country.

Through their foundation, Sanofi also donated EUR 5 million to the Red Cross for Ukraine and neighbouring countries and to UNHCR, the UN Refugee Agency. This will support emergency access to necessities such as food, shelter, medicine, and security, and will help receive and assist refugees from Ukraine.

In coordination with authorities and their partners, Sanofi is  accelerating the donation of their essential medicines and vaccines to support both patients in Ukraine and Ukrainian refugees in neighbouring countries. On 29th March, as their effort to support the European Commission’s ‘Stand Up For Ukraine' donation campaign, their foundation at Sanofi has donated nearly 300,000 vaccines to support diphtheria and tetanus vaccinations for Ukrainians. 200,000 shots will go to Ukraine, while another 70,000 will go to the Czech Republic, Slovakia and Moldova, which are hosting a significant number of Ukrainian refugees. (the European Commission Press Release)

In addition to Sanofi corporate donations, employee donations have also been organised across their affiliates.

Sanofi will continue to respond as the situation evolves.


Servier Group is mobilising through the various channels for aid and humanitarian relief being set up to help their employees, their families and the Ukrainian population. In addition, they are creating a “Ukraine Solidarity Fund” that has been endowed with EUR 700,000.

At the initiative of the Group’s employees, and to respond to their tremendous outpouring of support, a solidarity fund drive has opened up to give employees who would like to make personal donations the opportunity to do so. Likewise, the Group’s Generic Activities department has helped send an initial two-ton shipment of medical products and emergency kits through several NGOs.

Servier remain committed to ensuring that patients have access to the medicines that they need. They will do everything they can, with all their stakeholders, to limit the impact of the situation on the continuity of clinical trials, as well as on the supply and access to medicines that are essential for many patients in this region.

It is their fervent hope that Ukraine will soon be back on the path to peace.


Takeda are heartbroken by the ongoing humanitarian crisis in Ukraine and the impact on people living within the country and those who have had to flee their homes.

Their commitment to patients, regardless of where they live, and to their people is unwavering and is even more important in times of crisis. Takeda are making every effort to protect our colleagues in Ukraine and to continue to supply patients in Ukraine and in the region with much needed treatments.

Takeda are supporting the global humanitarian efforts by contributing JPY 300 million (approx. USD 2.6 million) to The International Federation of Red Cross and Red Crescent Societies, which is actively providing urgent local humanitarian support to people displaced and impacted by the conflict. Takeda are also donating medicines to hospitals working to provide care around the clock to patients in need, and will continue to evaluate ways to provide additional support services for patients and the treatment community. Takeda colleagues around the world are helping those in need in Ukraine by contributing with their personal donations to several local and global non-governmental organisations.

As the conflict and humanitarian crisis in Ukraine continues, Takeda are announcing an update to their company position in Russia.

Takeda has taken further action to discontinue activities in Russia that are not essential to maintaining supply of medicines to patients and providing ongoing support to their employees. This includes suspending all new investments, suspending advertising and promotion, not initiating new clinical trials and stopping enrolment of new patients in ongoing clinical trials.

Takeda's focus only on essential activities is consistent with their values and ethical responsibility to their patients in Ukraine, Russia and the region who depend on their treatments. Notwithstanding, Takeda are adhering to all international sanctions imposed on Russia.

Takeda will be increasing their humanitarian relief efforts, including monetary and medicine donations to benefit people affected by the conflict in Ukraine, and they will continue to assess new ways to provide support as they look to meet the needs of patients across the region.

Takeda will continue to monitor the situation closely and take appropriate actions grounded in their values.


Teva announced donations of essential medicines valued at over USD 11 million, extending humanitarian support of Ukrainian refugees. 

Teva has shipped over 1.3 million packs of medicines, including antibiotics and other medicines listed on the WHO's list of essential medicines, as well as products for Ukrainian infants and children struggling with poor hygienic conditions. 

Read the full release


In these difficult times, UCB is guided by their purpose of creating value for patients, now and in the future and their focus on contributing to a more inclusive and sustainable world. That’s why they are driven to limit the impact of this unfortunate war on their employees, patients and their respective communities.


UCB are fully focused on supporting the small group of UCB employees living in Ukraine, as well as their families, and they have foreseen emergency support for their colleagues.


UCB feel responsible to bring medicines to people living in Ukraine and Russia no matter how difficult the circumstances. They will do everything within their power to ensure patients have access to their medicines. This is extremely difficult because of disrupted supply chains.  In spite of this, UCB continue to investigate short and longer-term solutions to ensure availability of their medicines in the region.  UCB have a cooperation with NGOs such as Tulipe who are delivering drug donations to patients in the war zone. So far, UCB have donated more than 1,6 million doses of anti-epileptics and 35,000 daily doses of antihistamines. 


To support humanitarian efforts, UCB has donated EUR 300,000 to the German International Rescue Committee and the Belgian International Red Cross. They are also examining how they can support the communities in the region and those who have fled to safer places in the long-term, through our UCB Community Health Fund.

UCB colleagues around the world are showing solidarity, helping in refugee centres, making personal donations to charities, setting up collection of essential goods at UCB sites, driving to the Ukrainian border to pick up relatives or friends and hosting Ukrainian colleagues and refugees in their houses or those of other colleagues. These are only a few examples. To facilitate this much-needed movement of solidarity, they have developed an employee volunteering initiative to enable their colleagues in Europe to lend a helping hand to this enormous refugee crisis.

UCB in Russia

UCB is still bringing medicines to patients in Russia but they have reviewed the way in which they conduct our business there. Profits generated in Russia will be donated to the German International Rescue Committee and the Belgian International Red Cross to help the people of Ukraine. UCB have already stopped enrolling new patients and are not starting up any new sites or clinical trials in Russia. They are no longer undertaking marketing activities and are exploring other steps they can take to support the sanctions.

Vifor Pharma

In light of the developing humanitarian crisis in Ukraine, the thoughts of Vifor Pharma are with everyone affected - and in particular their patients, employees and their loved ones.

At Vifor Pharma, they are working hard to strengthen wider humanitarian efforts and have donated nearly 60,000 packages of iron therapies to help those in need in Ukraine. The use of the intravenous iron products in this emergency setting is hoped to improve surgical and medical outcomes in patients by optimal management of a patient’s additional transfusion needs during surgery as evidenced in the Patient Blood Management setting.

Vifor Pharma is a patient-centric company, and their greatest priority is to ensure that local healthcare organisations and patients receive the medicines they depend on in these uncertain times.

Last modified: 14 June 2022

Last reviewed: 14 June 2022